Towards Healthcare
Investigational New Drug CDMO Market Surges USD 5.66 Billion in 2025

Investigational New Drug CDMO Market Sees Growth in Injectable Demand, IND Approvals & Strategic Collaborations in 2025

Market insights predict, the investigational new drug CDMO industry is expected to grow from USD 5.29 billion in 2024 to USD 10.34 billion by 2034, driven by a CAGR of 6.97%. The investigational new drug CDMO market is expanding due to increasing developments in industries as well as growing cancer treatment approaches. North America led the market due to the presence of advanced industries.

Content

  • Insight Code: 5866
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The investigational new drug CDMO market is projected to reach USD 10.34 billion by 2034, growing at a CAGR of 6.97% from 2024 to 2034.

North America is currently leading the investigational new drug CDMO market due to the presence of advanced industries.

The investigational new drug CDMO market includes seven segments such as by molecule type, by service type, by phase, by therapeutic area, by end use, by dosage form, and by region.

Some key players include AGC Biologics, Albany Molecular Research Inc., Asymchem, and Cambrex.

Key trends include rising early-stage drug development for biotech companies globally and growth in the demand for antibody-drug conjugate (ADC) services.

IND CDMOs offer CMC development, API and drug product manufacturing, formulation, analytical testing, and regulatory documentation support tailored to preclinical, Phase I, and Phase II studies.

Growing developments in industries are the factor that drives the market.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions